A. Alcaraz,J. Gonzalez-Zuelgaray and F. Augustovski. Cost-Effectivity of Implantable Cardioverter Defibrillators in Patients with Risk Factors for Sudden Death in Argentina. Value in Health. 2011;14(5):10.1016/j.jval.2011.05.030.
S. G. Marti,A. Alcaraz,P. Valanzasca,O. U. Garay,M. McMullen,L. R. Ares,C. A. Obando and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS-C VIRUS INFECTION IN VENEZUELA. Value in Health. 2013;16(7).
S. G. Marti,A. Alcaraz,P. Valanzasca,U. G. Ulises,M. McMullen,L. R. Ares,I. Peirano,D. O. Reisberg,A. S. Ried,J. Poniachik,J. R. B. Barril and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN CHILE. Value in Health. 2013;16(7).
S. G. Marti,A. Alcaraz,P. Valanzasca,O. U. Garay,M. McMullen,L. R. Ares,V. Idrovo,J. P. Ortiz,M. Tapias,J. Obregon,J. G. Ariza and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN COLOMBIA. Value in Health. 2013;16(7).
S. G. Marti,A. Alcaraz,P. Valanzasca,U. G. Ulises,M. McMullen,L. R. Ares,I. Peirano,F. Bessone,H. Fainboim,A. Gadano,O. Galdame,C. Vujacich and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ARGENTINA. Value in Health. 2013;16(7).
R. Augustovski,A. Palacios,A. Beratarrechea,F. Diez-Canseco,V. Irazola,M. Ramirez-Zea,A. Pichon-Riyiere and A. Rubinstein. COST-EFFECTIVENESS ANALYSIS OF A RANDOMIZED TRIAL OF AN MHEALTH INTERVENTION TO IMPROVE CARDIOMETABOLIC PROFILE IN PREHYPERTENSIVE SUBJECTS FROM LOW-RESOURCE URBAN SETTINGS IN LATIN AMERICA. Value in Health. 2017;20(9).
L. Schluckebier,R. Caetano,O. U. Garay,G. T. Montenegro,M. Custodio,V. Aran and C. Gil Ferreira. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020;20(1):10.1186/s12885-020-07240-2.
A. Palacios,C. Mengarelli and F. Augustovski. COST ESTIMATION OF THE CHRONIC HEMODIALYSIS AND HEMODIALFILTRATION SERVICES IN ARGENTINA. Value in Health. 2017;20(9):10.1016/j.jval.2017.08.2523.
COST ESTIMATION OF THE CHRONIC HEMODIALYSIS AND HEMODIALFILTRATION SERVICES IN ARGENTINA Ver más »
D. Husereau,M. Drummond,F. Augustovski,E. de Bekker-Grob,A. H. Briggs,C. Carswell,L. Caulley,N. Chaiyakunapruk,D. Greenberg,E. Loder,J. Mauskopf,C. D. Mullins,S. Petrou,R. F. Pwu and S. Staniszewska. Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Appl Health Econ Health Policy. 2022;20(5):10.1007/s40258-022-00743-y.
D. Husereau,M. Drummond,S. Petrou,C. Carswell,D. Moher,D. Greenberg,F. Augustovski,A. H. Briggs,J. Mauskopf,E. Loder and I. H. E. E. Publica. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health. 2013;16(2):10.1016/j.jval.2013.02.002.
